Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Victoria K. Woodcock"'
Autor:
Mike B. Barnkob, Yale S. Michaels, Violaine André, Philip S. Macklin, Uzi Gileadi, Salvatore Valvo, Margarida Rei, Corinna Kulicke, Ji-Li Chen, Vitul Jain, Victoria K. Woodcock, Huw Colin-York, Andreas V. Hadjinicolaou, Youxin Kong, Viveka Mayya, Julie M. Mazet, Gracie-Jennah Mead, Joshua A. Bull, Pramila Rijal, Christopher W. Pugh, Alain R. Townsend, Audrey Gérard, Lars R. Olsen, Marco Fritzsche, Tudor A. Fulga, Michael L. Dustin, E. Yvonne Jones, Vincenzo Cerundolo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Semaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely
Externí odkaz:
https://doaj.org/article/0037fd20318049ccb1e0d08f25e77331
Autor:
Victoria K. Woodcock, Ji‐Li Chen, Karin Purshouse, Chrissie Butcher, Linda Collins, Caroline Haddon, Gillian Verrall, Leena Elhussein, Corran Roberts, Andrea Tarlton, Margarida Rei, Giorgio Napolitani, Mariolina Salio, Mark R. Middleton, Vincenzo Cerundolo, Jeremy Crew, Andrew S. Protheroe
Publikováno v:
BJUI Compass, Vol 4, Iss 3, Pp 322-330 (2023)
Abstract Objectives This study aimed to investigate the anti‐PD‐1 inhibitor pembrolizumab as a potential agent for use in non‐muscle‐invasive bladder cancer (NMIBC) by conducting a Phase 1 safety run‐in study to assess the safety and tolera
Externí odkaz:
https://doaj.org/article/d7395c1210aa4beeac995f4f6e98382c
Autor:
Mike B. Barnkob, Yale S. Michaels, Violaine André, Philip S. Macklin, Uzi Gileadi, Salvatore Valvo, Margarida Rei, Corinna Kulicke, Ji-Li Chen, Vitul Jain, Victoria K. Woodcock, Huw Colin-York, Andreas V. Hadjinicolaou, Youxin Kong, Viveka Mayya, Julie M. Mazet, Gracie-Jennah Mead, Joshua A. Bull, Pramila Rijal, Christopher W. Pugh, Alain R. Townsend, Audrey Gérard, Lars R. Olsen, Marco Fritzsche, Tudor A. Fulga, Michael L. Dustin, E. Yvonne Jones, Vincenzo Cerundolo
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/c91684507e624290b137868f21bb7e7e
Autor:
Mario Sznol, Ita O’Kelly, Jacob Hurst, Sion Lewis, Sarah Stanhope, Revashnee Naidoo, Emma Leach, Antonella Vardeu, Avinash Gupta, Omid Hamid, Alexander N. Shoushtari, Alan Anthoney, Thomas R. Jeffry Evans, Neil M. Steven, Jeffrey R. Infante, Pippa Corrie, Victoria K. Woodcock, Cheryl McAlpine, Mark R. Middleton
Supplementary material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c150f85250c5fc5cf0680722bad89c5b
https://doi.org/10.1158/1078-0432.22476341.v1
https://doi.org/10.1158/1078-0432.22476341.v1
Autor:
Mario Sznol, Ita O’Kelly, Jacob Hurst, Sion Lewis, Sarah Stanhope, Revashnee Naidoo, Emma Leach, Antonella Vardeu, Avinash Gupta, Omid Hamid, Alexander N. Shoushtari, Alan Anthoney, Thomas R. Jeffry Evans, Neil M. Steven, Jeffrey R. Infante, Pippa Corrie, Victoria K. Woodcock, Cheryl McAlpine, Mark R. Middleton
Purpose:Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ccbf030ab20eb31d6aefca0fa390978
https://doi.org/10.1158/1078-0432.c.6529373
https://doi.org/10.1158/1078-0432.c.6529373
Autor:
Chelsea A. Taylor, Robert A. Watson, Orion Tong, Weiyu Ye, Isar Nassiri, James J. Gilchrist, Alba Verge de los Aires, Piyush Kumar Sharma, Surya Koturan, Rosalin A. Cooper, Victoria K. Woodcock, Elsita Jungkurth, Brian Shine, Nicholas Coupe, Miranda J. Payne, David N. Church, Vivek Naranbhai, Stefan Groha, Paul Emery, Kulveer Mankia, Matthew L. Freedman, Toni K. Choueiri, Mark R. Middleton, Alexander Gusev, Benjamin P. Fairfax
Publikováno v:
Nature medicine. 28(12)
Treatment with immune checkpoint blockade (ICB) frequently triggers immune-related adverse events (irAEs), causing considerable morbidity. In 214 patients receiving ICB for melanoma, we observed increased severe irAE risk in minor allele carriers of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10b9965e7948bb4b13ce5c06561db93
https://pubmed.ncbi.nlm.nih.gov/36526722
https://pubmed.ncbi.nlm.nih.gov/36526722
Autor:
Alexander N. Shoushtari, Neil Steven, Cheryl McAlpine, Jeffrey R. Infante, Revashnee Naidoo, Sarah Stanhope, Ita O’Kelly, Omid Hamid, Victoria K Woodcock, Pippa Corrie, Mark R. Middleton, Emma Leach, Alan Anthoney, Sion Lewis, Jacob Hurst, Avinash Gupta, Antonella Vardeu, Thomas R. Jeffry Evans, Mario Sznol
Publikováno v:
Clinical Cancer Research. 26:5869-5878
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d07ec411dced4f8bcfe606fe87d76573
https://doi.org/10.1158/1078-0432.ccr-20-1247
https://doi.org/10.1158/1078-0432.ccr-20-1247
Autor:
Julian C. Knight, Isar Nassiri, Miranda Payne, S Danielli, Paul Klenerman, Robert A. Watson, Chelsea A Taylor, Rosalin Cooper, Benjamin P. Fairfax, Zoë C. Traill, E Mahe, Hai Fang, Mark R. Middleton, Hussein Al-Mossawi, Victoria K Woodcock
Publikováno v:
Nature medicine
Immune checkpoint blockade (ICB) of PD-1 and CTLA-4 to treat metastatic melanoma (MM) has variable therapeutic benefit. To explore this in peripheral samples, we characterized CD8+ T cell gene expression across a cohort of patients with MM receiving
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b4d70fa6a9a24476a3b000287fe0bd4
http://europepmc.org/articles/PMC7611047
http://europepmc.org/articles/PMC7611047
Autor:
Yazhuo Kong, Viveka Mayya, M Rei, Christopher W. Pugh, Michael L. Dustin, Lars Rønn Olsen, Tudor A. Fulga, Victoria K Woodcock, Kulicke Ca, Marco Fritzsche, V. Jain, Andreas V. Hadjinicolaou, E Y Jones, Chen J-L., V Andre, Pramila Rijal, Mike Bogetofte Barnkob, Joshua A. Bull, Uzi Gileadi, Huw Colin-York, Vincenzo Cerundolo, Salvatore Valvo, Alain Townsend, Yale S. Michaels, Philip S. Macklin
Semaphorin-3A (Sema3A) regulates tumor angiogenesis, but its role in modulating anti-tumor immunity is unclear. We demonstrate that Sema3A secreted within the tumor microenvironment (TME) suppresses tumor-specific CD8+ T cell function via Neuropilin-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3695ba007bc288ca11964d5920f42855
Autor:
Sophie Postel-Vinay, Flavio Ewerton, Matthias Ocker, Neil Benson, Jean-Charles Soria, Martine Poelman, Karin H Herbschleb, Gary Wilkinson, Mark R. Middleton, Victoria K Woodcock, Annette O. Walter, Christophe Massard
Publikováno v:
European Journal of Cancer. 109
Background: Bromodomain and extraterminal motif (BET) protein inhibition is a promising cancer treatment strategy, notably for targeting MYC- or BRD4-driven diseases. A first-in-human study investigated the safety, pharmacokinetics, maximum tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40cdf9edd7e6784239b4795f3375835b
http://ora.ox.ac.uk/objects/uuid:
http://ora.ox.ac.uk/objects/uuid: